SyntheticMR AB

SYNT

SE0015987946

Advanced Medical Equipment & Technology

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-01-30 pm EST			5-day change	1st Jan Change
27.7 ^SEK	+1.09%		-.--%	+4.14%

Apr. 17	SyntheticMR AB and SimonMed Imaging Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from Synthetic Software at SimonMed Facilities	CI
Mar. 27	SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D	CI

Syntheticmr AB Proposes No Dividend Will Be Paid for the Full Year 2020

February 18, 2021 at 02:11 am EST

The Board of Directors of SyntheticMR AB (publ) proposes to the AGM that no dividend will be paid due to the 2020 results.

Latest news about SyntheticMR AB

SyntheticMR AB and SimonMed Imaging Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from Synthetic Software at SimonMed Facilities	Apr. 17	CI
SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D	Mar. 27	CI
Royal Philips Partners SyntheticMR to Roll Out New Brain Disorder Diagnosis Technology	Mar. 01	MT
SyntheticMR AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20	CI
SyntheticMR AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking	Dec. 18	CI
SyntheticMR Receives Order from an OEM Partner	Dec. 13	CI
SyntheticMR Extends Partnership with Philips to Include SyMRI 3D	Nov. 30	MT
SyntheticMR and Philips Announces Expands Global Partnership for SyMRI 3D	Nov. 30	CI
SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance	Nov. 22	CI
SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting	Nov. 17	CI
SyntheticMR AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
SyntheticMR AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11	23-06-15	CI
SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow	23-06-13	CI
SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea	23-05-31	CI
SyntheticMR AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
SyntheticMR's Receives Regulatory Clearance for SyMRI in the UK	23-03-02	CI
Syntheticmr AB's Innovative Software Receives Regulatory Approval in Canada	23-02-27	CI
SyntheticMR AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI
SyntheticMR AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15	CI
SyntheticMR Signs Sales Agreement Regarding SyMRI NEURO	22-12-08	CI
SyntheticMR AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
SyntheticMR Receives EU Medical Device Regulation Certificate	22-10-28	CI
SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil	22-10-07	CI

SyntheticMR AB (publ) is a Sweden-based company that develops and markets software solutions for Magnetic Resonance Imaging (MRI). The Company provides SyMRI, which measures the absolute properties of the brain and delivers adjustable contrast images, automatic biomarker segmentation and quantitative data in a single MR scan. The SyMRI product is available in different packages. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps, parametric common contrast weighted images and maps of the brain, allowing the investigation to be taken even further. SyMRI is a registered trademark in Europe and in the USA.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for SyntheticMR AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.7 SEK

Average target price

30 SEK

Spread / Average Target

+8.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
SYNTHETICMR AB	+4.14%	106M
VEEVA SYSTEMS INC.	+4.36%	32.18B
PRO MEDICUS LIMITED	+14.14%	7.33B
SECTRA AB	+22.93%	3.83B
EVOLENT HEALTH, INC.	-16.29%	3.23B
OMNICELL, INC.	-25.96%	1.25B
LUNIT INC.	-36.14%	1.12B
SIMULATIONS PLUS, INC.	-0.13%	912M
B-SOFT CO.,LTD.	-35.42%	859M
VERADIGM INC.	-24.12%	856M

Medical Software & Technology Services

SyntheticMR AB

Equities

SYNT

SE0015987946

Advanced Medical Equipment & Technology

Syntheticmr AB Proposes No Dividend Will Be Paid for the Full Year 2020

Latest news about SyntheticMR AB

Chart SyntheticMR AB

Company Profile

Income Statement Evolution

Ratings for SyntheticMR AB

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical Software & Technology Services